Robust QCM-Based Sensing and Assay Formats in Commercialized Systems
In the forthcoming book on "Mass-sensitive sensors" which is part of the "Springer Series on Chemical Sensors and Biosensors", Attana has written the chapter on commercial aspects for mass-sensitive sensors. Attana's biosensors are used to exemplify important aspects on how to go from science to industrial and commercial applications. The chapter is available (payment function) here: https://link.springer.com/chapter/10.1007/5346_2023_29#chapter-info
The book series aims to publish articles that can serve as important tools for both industry and researchers working in this interdisciplinary field. The carefully selected collection of publications aims to provide continuous inspiration for new research and development and highlight technologies that can generate great humanitarian and commercial value.
The main editor of the book is Professor Peter Lieberzeit at the University of Vienna and the team at Attana has written the chapter together with Dr Nicholas Jones, Withers & Rogers (IP) and Professor Ian Nicholls and Dr Subramanian Suriyanarayanan at Linnaeus University.
The chapter "Robust QCM-Based Sensing and Assay Formats in Commercialized Systems" describes how Attana's analytical instrument functions and is applied.
Attana's unique and patented technology for kinetic interaction studies makes it possible to perform various analyzes in real time on human cells and tissue as well as in blood. With a focus on optimizing, selecting, and validating drug candidates before clinical trials, Attana has helped pharmaceutical companies to streamline their drug process and these companies are significantly more in clinical studies than the industry average.
For Attana, the book is important as it provides strong recognition for Attana's world-leading technology in the biosensor market. The chapter will be able to be used as an introduction for many potential customers, as it provides a good summary of opportunities to perform more body-like studies and how these studies are carried out in practical terms.
For more information, please contact:
Marcus Söderberg
CEO Attana AB
ir@attana.com
+46 708 86 23 00
The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price but is of general interest for the shareholders and hence should be communicated.
About Attana
Attana was founded in 2002 with the vision of in vitro characterization of molecular interactions mimicking in vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.com or contact sales@attana.com
Tags: